85-4423-73 [取扱停止]Fibroblast Growth Factor 19, Recombinant, Human (FGF-19) 5ug 299369
特徴
- The FGFs are a family of more than 20 small (~17-26kD) secreted peptides. The initial characterization of these proteins focused on their ability to stimulate fibroblast proliferation. This mitogenic activity was mediated through FGF receptors (FGFRs) 1, 2, or 3. A fourth closely related tyrosine kinase receptor (FGFR4) was able to bind the FGFs but did not lead to a mitogenic response. FGFs modulate cellular activity via at least 5 distinct subfamilies of high-affinity FGF receptors (FGFRs): FGFR-1, -2, -3, and -4, all with intrinsic tyrosine kinase activity and, except for FGFR-4, multiple splice isoforms, and FGFR-5, which lacks an intracellular kinase domain. There is growing evidence that FGFRs can be important for regulation of glucose and lipid homeostasis. The overexpression of a dominant negative form of FGFR-1 in beta cells leads to diabetes in mice, which thus implies that proper FGF signaling is required for normal beta cell function and glycemia maintenance. FGFR-2 appears to be a key molecule during pancreatic development. Moreover, FGFR-4 has been implicated in cholesterol metabolism and bile acid synthesis. FGF-19, has been shown to cause resistance to diet-induced obesity and insulin desensitization and to improve insulin, glucose, and lipid profiles in diabetic rodents. Since these effects, at least in part, are mediated through the observed changes in metabolic rates, FGF-19 can be considered as a regulator of energy expenditure. FGF-21 is preferentially expressed in liver, but an exact knowledge of FGF-21 bioactivity and its mode of action have been lacking to date. FGF-21 is a potent activator of glucose uptake on adipocytes, protects animals from diet-induced obesity when overexpressed in transgenic mice, and lowers blood glucose and triglyceride levels when therapeutically administered to diabetic rodents.
- Source:Recombinant protein corresponding to 206aa from human FGF-19, expressed in E. coli.
- Molecular Weight:~23kD
- AA Sequence: MRGSHHHHHH GMASLAFSDA GPHVHYGWGD PIRLRHLYTS GPHGLSSCFL RIRADGVVDC ARGQSAHSLLEIKAVALRTV AIKGVHSVRY LCMGADGKMQ GLLQYSEEDC AFEEEIRPDG YNVYRSEKHR LPVSLSSAKQ RQLYKNRGFL PLSHFLPMLP MVPEEPEDLR GHLESDMFSS PLETDSMDPF GLVTGLEAVR SPSFEK
- Storage and Stability:Lyophilized powder may be stored at -20°C. Stable for 12 months after receipt at -20°C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
仕様
- Size:5ug
- Source Antigen:Recombinant, E. coli
- Grade:Highly Purified
- Purity:~95% (RP-HPLC, SDS-PAGE)
- Form:Supplied as a lyophilized powder in 10mM Tris, pH 7.6, 100mM sodium chloride. Reconstitute with sterile ddH2O. For long term storage, it is recommended to add a carrier protein (0.1% HSA or BSA).
- Molecular Weight Non Ab:23
- EU Commodity Code:30021019
- この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)
- 製品の仕様は予告なく変更になる場合がございます。最新仕様はメーカーホームページをご確認ください。
- 【試薬に関するお問合せ】
- アズワン株式会社 試薬・プロセス材料グループ
- TEL:06-6447-8641
- FAX:06-6447-8642
- E-mail:[email protected]
商品のバリエーション (サイズ違い・スペック違い・オプション品など)
| 商品イメージ | アズワン品番 商品名 |
|---|---|
|
85-4423-74
Fibroblast Growth Factor 19, Recombinant, Human (FGF-19) 25ug
|
|
|
85-4423-73
Fibroblast Growth Factor 19, Recombinant, Human (FGF-19) 5ug
|
よくあるご質問(FAQ)
掲載カタログ情報
| 掲載カタログ名 | 掲載ページ |
|---|





